Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Vadim S KoshkinNicholas HendersonMarihella JamesDivya NatesanDory FreemanAmanda NizamChristopher T SuAli Raza KhakiChelsea K OstermanMichael J GloverRyan ChiangDimitrios MakrakisRafee TalukderEmily LemkeT Anders OlsenJayanshu JainAlbert JangAlicia AliTanya JindalJonathan ChouTerence W FriedlanderChristopher HoimesArnab BasuYousef ZakhariaPedro C BarataMehmet A BilenHamid EmamekhooNancy B DavisSumit A ShahMatthew I MilowskyShilpa GuptaMatthew T CampbellPetros D GrivasGuru P SonpavdeDeepak KilariAjjai S AlvaPublished in: Cancer (2021)
Enfortumab vedotin, approved by the Food and Drug Administration in 2019, is an important new drug for the treatment of patients with advanced bladder cancer. This study looks at the effectiveness of enfortumab vedotin as it has been used at multiple centers since approval, and focuses on important patient populations previously excluded from clinical trials. These populations include patients with decreased kidney function, diabetes, and important mutations. Enfortumab vedotin is effective for treating these patients. Previously reported clinical trial data have been replicated in this real-world setting, and support the use of this drug in broader patient populations.
Keyphrases
- clinical trial
- drug administration
- hodgkin lymphoma
- papillary thyroid
- end stage renal disease
- case report
- randomized controlled trial
- chronic kidney disease
- type diabetes
- systematic review
- high grade
- cardiovascular disease
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- squamous cell
- peritoneal dialysis
- prognostic factors
- genetic diversity
- electronic health record
- study protocol
- big data
- metabolic syndrome
- machine learning
- drug induced
- artificial intelligence
- adipose tissue
- data analysis
- adverse drug
- double blind